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E-mail address: drjung@snu.ac.kr (G. Jung).Catalase, which decomposes reactive oxygen species (ROS), is reduced in hepatocellular carcinoma
(HCC); however, the reasons are poorly deﬁned. In this study, it is demonstrated that prolonged
exposure to ROS induced methylation of CpG island II on the catalase promoter and downregulated
catalase expression at the transcriptional level in HCC cell lines. In addition, hypermethylation of
CpG island II was also observed in tumor tissues, together with a decrease in catalase mRNA and pro-
tein expression levels when compared to non-tumor tissues. From these data, we suggest that ROS
may downregulate catalase through the methylation of promoter during the development of HCC.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Catalase is a 240-kDa homotetrameric enzyme that catalyzes
the decomposition of extracellular and intracellular hydrogen per-
oxide (H2O2) and plays a key role in protecting cells against reac-
tive oxygen species (ROS) [1]. The expression of catalase is
decreased in hepatocellular carcinoma (HCC), as well as in other
types of cancers [2,3]. A loss in catalase activity during cancer
development is associated with tumor formation and metastasis
[4–6].
ROS, such as superoxide radicals, hydroxyl radicals, and H2O2,
contribute to tumor progression by promoting DNA damage and/
or altering cell signaling pathways [7]. ROS are involved in tumor
metastasis, which is a complex process involving epithelial-to-
mesenchymal transition, migration, invasion, and angiogenesis
within the tumor microenvironment [8].
Epigenetic gene silencing can be caused by an aberrant methyl-
ation of gene promoters [9–11], and it plays an essential role in thechemical Societies. Published by E
DNMT, DNA methyltransfer-
n-speciﬁc polymerase chain
ne methosulfate; BS, sodium
iological Sciences and Seoul
k-gu, Seoul 151-742, Southregulation of chromatin structure formation and gene expression
in general. DNA methylation, which can result in the loss of gene
function, also promotes cancer development by repressing tumor
suppressor genes [12].
HCC is a common fatal malignancy that results in approxi-
mately one million deaths per year, worldwide [13]. Oxidative
stress is the most important causative factor of HCC [14].
The present study shows that catalase is epigenetically silenced
in HCC cell lines following prolonged exposure to ROS. Further-
more, catalase was found to be downregulated in tumor tissues
when compared with non-tumor tissues. This difference in expres-
sion level may be attributed to differences in the methylation sta-
tus of the catalase promoter.2. Materials and methods (see Supplementary data)
2.1. Cell culture
The human hepatoma cell lines Hep3B and Huh7 were cultured
in Dulbecco’s modiﬁed Eagle’s medium with 10% fetal bovine ser-
um (FBS) (Invitrogen, Carlsbad, CA, USA). For ROS treatment, the
medium was changed daily for fresh medium with 10% FBS and
the cells were incubated for 4 days with 300 lM H2O2 and 2 lM
phenazine methosulfate (PMS). For some experiments, the cells
were pretreated with 5 mM N-acetylcysteine (Sigma–Aldrich, St.
Louis, MO, USA) and 2 lM 5-aza-20-deoxycytidine (5-aza-dC)
(Sigma–Aldrich) for 30 min before the addition of H2O2 and PMS.lsevier B.V. All rights reserved.
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One microgram of genomic DNA was treated with sodium
bisulﬁte using the EpiTect Bisulﬁte kit (Qiagen, Valencia, CA,
USA). To analyze the methylation status of the catalase promoter,
primers for MSP were designed using the Methyl Primer Express
software (Applied Biosystems, Foster City, CA, USA). The sequencesFig. 1. Reactive oxygen species downregulate catalase expression in hepatocellular carci
the location of PCR primer binding sites. (B) Hep3B and Huh7 cells were treated with 30
methylation-speciﬁc PCR (MSP) was performed. SM, Size marker; U, unmethylated DNA;
ampliﬁed with sodium bisulﬁte genomic sequencing (BS) primers. h, Unmethylated CpG
PCR. (E) Catalase expression was assessed by immunoblot analysis of cell lysates prepared
described in Section 2. (G) The catalase promoter deletion constructs are schematically re
or non-methylated pGL3-serially-deleted catalase promoters, together with a Renilla lu
were lysed 48 h after transfection, and the luciferase activity in the cell lysates was m
experiments performed in duplicates.of the oligonucleotide primers are provided in Supplementary
Table 1.
2.3. Immunoblot analysis
The detailed methods for immunoblot analysis have been de-
scribed previously [15]. Antibodies used in this study includednoma (HCC) cell lines. (A) Distribution of CpG islands on the catalase promoter and
0 lM H2O2 and 2 lM phenazine methosulfate (PMS) for 2, 4 and 6 days, after which
M, methylated DNA; PMS, phenazine methosulfate. (C) Bisulﬁte-modiﬁed DNA was
site; j, methylated CpG site. (D) Catalase expression was assessed by real-time RT-
as described in (B). (F) Catalase activity was measured using cell lysates prepared as
presented (left). Huh7 cells were cotransfected with each of the different methylated
ciferase expression vector (pRL-SV40) as a control for transfection efﬁciency. Cells
easured. Error bars represent the mean standard deviation (S.D.) of at least three
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ma–Aldrich).3. Results
3.1. ROS induce methylation of the catalase promoter
To determine the effects of long exposure to ROS, HCC cell lines
were treated with H2O2 and PMS as ROS sources [15] for 6 days.
The effect of these ROS on the methylation of the catalase promoter
was analyzed using MSP analysis (Fig. 1A and B). We speciﬁcally
selected the CpG island II region located in the catalase promoter
and excluded the CpG island I because it was already methylated
in HCC cells (see Supplementary Fig. 1). The methylation of CpG is-
land II was observed 4 days after ROS treatment, as determined by
MSP analysis and sodium bisulﬁte genomic sequencing (BS). The
mean methylation status of control cells was approximately
1.11%, whereas that of H2O2-treated cells was 28.52% (Fig. 1C).
Real-time RT-PCR, immunoblot analysis and catalase activity assay,
performed with the same cells, demonstrated that catalase mes-
senger RNA (mRNA) (Fig. 1D), protein (Fig. 1E) and catalase activity
(Fig. 1F), respectively, were also reduced.
Thus, these results showed that prolonged exposure to ROS in-
duced methylation of CpG island II on the catalase promoter and
simultaneously downregulated catalase expression and activity
in HCC cell lines.Fig. 2. N-Acetylcysteine and 5-aza-20-deoxycytidine restore catalase expression in ROS-
2 lM phenazine methosulfate (PMS), and/or 5 mM N-acetylcysteine and 2 lM 5-aza-dC
cells. (B) Catalase expression was assessed by real-time RT-PCR. (C) Catalase expression w
lysates of the cells treated as described in (A).To assess whether methylation of the catalase promoter causes
any changes in its transcriptional activity, serial deletion analysis
of catalase promoter constructs was performed using a dual lucifer-
ase assay in combination with an in vitro methylation assay. Each
promoter-luciferase expression plasmid was mock-methylated or
methylated with the CpG methyltransferase, M. SssI (see Supple-
mentary Fig. 2), and used to transfect Huh7 cells. Methylation of
the human catalase promoter suppressed the expression of the re-
porter gene although different promoter constructs had different
levels of promoter activities (Fig. 1G). However, the activity of the
M. SssI-methylated pGL3-basic plasmid was almost the same when
unmethylated, implying that the M. SssI-mediated methylation re-
duced the catalase promoter-driven transcription speciﬁcally with-
out affecting the vector. In addition, the insert DNA was digested,
gel-puriﬁed, and then methylated or mock-methylated in vitro be-
fore religation with the KpnI/BglII-digested pGL3 vector (see Sup-
plementary Fig. 3); the recombinant plasmid was then transfected
into Huh7 cells. Since, M. SssI-methylated not only the catalase pro-
moter fragment but also the open reading frame (ORF) of the lucif-
erase gene, we performed additional experiment.
These data show that the methylation of CpG sites on the cata-
lase promoter caused a reduction in the promoter activity.
3.2. N-Acetylcysteine and 5-aza-dC restore catalase expression
Methylation of the catalase promoter was inhibited following
the treatment of cells with N-acetylcysteine, an antioxidant or withtreated HCC cell lines. (A) Hep3B and Huh7 cells were treated with 300 lM H2O2,
for 4 days, after which MSP was performed using genomic DNA isolated from these
as assessed by immunoblot analysis. (D) Catalase activity was measured using cell
Table 1
Correlation between the decrease in catalase expression and methylation of CpG
island II on the catalase promoter in HCC tissues.
Grade Characteristics N = 30
HCC G
III












G III, Edmondson-Steiner grade III.
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Concomitantly, catalase mRNA (Fig. 2B), protein (Fig. 2C), and cat-
alase activity (Fig. 2D) were restored in these cells. These results
suggest a correlation between prolonged exposure to ROS stress,
downregulation of catalase, and methylation of the catalase
promoter.
To determine whether catalase downregulation by ROS was
reversible, cells were treated with H2O2 for 4 days and changed
the fresh medium lacking H2O2, and incubated the cells for an
additional 4 days. MSP analysis was performed to examine the
methylation status of CpG island II on the catalase promoter. After
removal of H2O2 from the medium, CpG island II was found to be
demethylated (see Supplementary Fig. 4A). Catalase mRNA, protein
expression and activity (see Supplementary Fig. 4B–D) were de-
creased upon ROS treatment, but 4 days after the removal of ROS
treatment, these levels had again increased.
From these data, it was observed that ROS-mediated methyla-
tion of the catalase promoter and downregulation of catalase
expression is reversible in HCC cell lines.
3.3. Methylation of CpG island II on the catalase promoter and
downregulation of catalase expression in HCC tissues
To determine the methylation status of the catalase promoter,
the promoter region in 30 samples of grade III HCC tissues wereFig. 3. Methylation status of the catalase promoter and the expression of catalase in HCC
was determined by MSP of genomic DNA from grade III HCC tissues. SM, Size marker; N
Methylation analysis of CpG island II present on the catalase promoter in tumor tissue and
clones from tumor tissue and 10 clones from non-tumor tissues were analyzed for
Unmethylated CpG site; j, methylated CpG site. (C) Catalase expression was assessed
catalase and b-actin-speciﬁc antibodies was performed with tumor and non-tumor tissuanalyzed. CpG island I on the catalase promoter was found to be
completely methylated in both tumor and non-tumor tissues.
However, CpG island II was methylated at a greater frequency in
tumor tissues than the non-tumor tissues (Fig. 3A). Twenty-one
(70%) of the 30 tissues showed a decrease in catalase expression,
while MSP analysis showed methylation of the catalase promoter
in 73.33% (22/30) of the grade III tissues revealed (Fig. 3A). In the
21 cases in which catalase was downregulated, nineteen (63.33%)
were accompanied by promoter methylation (Fig. 3A, Table 1). BS
of the HCC tissues revealed that CpG island II was methylated to
a higher extent in tumor tissues than in non-tumor tissues
(Fig. 3B and see Supplementary Fig. 5). Because mRNA from thesetissues. (A) The methylation status of CpG islands I and II on the catalase promoter
, non-tumor tissue; T, tumor tissue; U, unmethylated DNA; M, methylated DNA. (B)
non-tumor tissue pairs as evaluated by BS (Supplementary data and Section 2). Ten
CpG dinucleotide methylation. Each arrow represents a primer binding site. h,
by real-time RT-PCR. N, Number of cases. *P < 0.05. (D) Immunoblot analysis using
es. An anti-b-actin antibody was used as a control for protein loading.
J.Y. Min et al. / FEBS Letters 584 (2010) 2427–2432 2431tissue samples was unavailable, we used other grade III tissues, in
which CpG island II was methylated. Catalase expression was low-
er in grade III HCC tissues than in non-tumor tissues (Fig. 3C). This
decrease in catalase expression in the tumor tissues was also con-
ﬁrmed by immunoblot analysis (Fig. 3D).
Altogether, these results indicate that a signiﬁcant correlation
exists between prolonged exposure to ROS stress, downregulation
of the catalase expression, and methylation of the catalase pro-
moter in HCC tissues.4. Discussion
Here, we showed that ROS may downregulate the expression of
catalase at the transcriptional level in HCC cells. We observed that
DNA methylation abolished the transcriptional activity of the cat-
alase promoter. Furthermore, we found downregulated catalase
mRNA levels in human HCC tissues. These ﬁndings suggest that
catalase downregulation by ROS occurred in both our ROS-treated
cells and in patient tumor tissues. From the data of HCC cells and
human HCC tissues we thus conﬁrmed that exposure to ROS stress
is signiﬁcantly associated with catalase downregulation and meth-
ylation of the catalase promoter during the development of HCC.
In our previous study, we showed that changes in ROS stress
markers, decreased the expression of antioxidant enzymes such
as Cu/Zn superoxide dismutase (SOD) or catalase, and increased
DNA damage and that these changes positively correlated with
the differentiation grade of HCC, which, in turn, correlated with
vascular invasion. An overexpression of catalase can inhibit the
invasiveness of HCC cells as well as decrease the intracellular
ROS levels [15]. These data, together with the data for changes in
the degree of differentiation, imply that the greater the increase
in ROS stress, the more extensive is the methylation of the catalase
promoter. Thus, catalase plays an important role in inhibiting vas-
cular invasion during tumor progression.
Many studies have shown that catalase expression may be reg-
ulated by aberrant methylation during the progression of mouse
skin tumors and that catalase activity is attenuated during malig-
nant progression of mouse keratinocytes [16,17]. These studies,
however, did not address the epigenetic relationship between
ROS and the methylation status of the catalase promoter in tumor
tissues. In the present study, we conﬁrmed this relationship in
human HCC cell lines, but not in mouse cell lines. Moreover, this
is the ﬁrst study to validate that the catalase promoter is methyl-
ated in cases of human HCC.
Ding et al. reported that 3.3% of the catalase promoter sequence
is hypermethylated in HCC. In our study, however, 73.33% of the
promoter sequence was methylated in HCC cells. This discrepancy
in the methylation status is probably because different sites were
analyzed in the two studies. Unlike the previous study, which fo-
cused on the region downstream (+118 to +372) of the transcrip-
tion initiation site, our study focused on the region upstream
(204 to 14) of the transcription initiation site, on CpG island II
[18].
The methylation frequency of the catalase promoter is substan-
tially lower than that of promoters of other tumor suppressor
genes that undergo methylation-based regulation, such as p21
and E-cadherin [15,19]. Previous studies also veriﬁed that methyl-
ation interferes with the binding of transcriptional activators to the
promoter, thereby reducing the level of transcription. Several tran-
scriptional activators bind to the catalase promoter [20,21]. Cata-
lase downregulation could be regulated by an analogous
mechanism in which the binding of the activator to the promoter
is hindered by methylation.
Short-term exposure of HCC cells to ROS increases the expres-
sion of catalase (see Supplementary Fig. 6). However, prolongedexposure to ROS decreases catalase expression because the meth-
ylation of the catalase promoter. This ﬁnding implies that the cells
probably lose their defense mechanism against ROS, which facili-
tates the progression of cancer. Because of the reduced capacity
to eliminate ROS, ROS levels are increased. This process is accom-
panied by signiﬁcant intracellular changes, such as reduction in
E-cadherin levels, as observed by changes in the E-cadherin repres-
sor Snail [15].
In this study, we did not investigate whether ROS directly cause
methylation of the catalase promoter in tumor tissues. Further
studies should focus on identifying the putative ROS-mediated
pathway that affects DNA methylation. Nevertheless, our results
strongly suggest that ROS affect the methylation status of the cat-
alase promoter during carcinogenesis.
Thus, we propose the presence of a functional pathway involv-
ing ROS-induced epigenetic changes in which persistently elevated
ROS induce methylation of CpG island II of the catalase promoter in
HCC cells. We have validated our hypothesis with data from hu-
man tissues. Our ﬁndings may suggest new therapeutic approaches
for curing HCC by targeting the catalase promoter.
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